Area of research
Ophthalmology · Immunology
Research interest
Research interests include Ocular Oncology and Treatments, Immunotherapy and Immune Responses, Occupational and environmental lung diseases, and Cancer Immunotherapy and Biomarkers.
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
Advances in the clinical management of uveal melanoma
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study